Psychedelics and Psychedelic-Assisted Therapy: Definitions, Effects and How to Weigh Claims
Psychedelic-Assisted Medicine: Science and Practice
Learning objectives for this lesson:
- Define the classic serotonergic psychedelics by their shared action at the serotonin 2A receptor, and distinguish them from the entactogen MDMA, the dissociative ketamine and the atypical agents ibogaine and salvinorin A.
- Explain why pharmacological groups, Canadian drug schedules and national survey categories sort the same substances in different ways.
- Describe psychedelic-assisted therapy as a phased process of screening, preparation, supervised dosing and integration, and contrast it with a daily medication and with supervised esketamine.
- Identify the authorized routes through which psychedelic-assisted therapy with a controlled substance can lawfully take place in Canada as of October 2026.
- Describe the perceptual, emotional, cognitive and self-related effects of psychedelics, and explain how the 5D-ASC, MEQ30, Ego Dissolution Inventory and Challenging Experience Questionnaire measure them.
- Explain what research scales, qualitative studies and user-reported sources such as PsychonautWiki can and cannot establish.
- Interpret Canadian and United States survey estimates of psychedelic use, including the effects of questionnaire changes, and summarize the evidence on microdosing, retreats and unlicensed storefronts.
- Explain the hype cycle as it has been applied to the growth of psychedelic research, and apply a six-item checklist (design, comparator, blinding, sample, follow-up and funding) to real claims from trial reports, company announcements, press releases and storefronts.
This course was developed by Dr. Kiffer G. Card.
Defining the Field: Classes of Psychedelics and What Makes a Therapy Psychedelic-Assisted
Introduction
Every claim in this course depends on knowing which substance is being discussed. The word “psychedelic” appears in news about mushroom storefronts, in reports of clinical trials for depression and in the names of companies that sell nasal sprays, and it is applied to drugs that act on quite different molecular targets. A reader who learns that “a psychedelic” helped people with post-traumatic stress disorder needs to know whether the trial used MDMA, psilocybin or ketamine, because the three drugs act differently, carry different risks and are regulated differently in Canada.
Part 1.1 separates the narrow pharmacological meaning of the word from its broader everyday use, and Part 1.2 sorts the substances into four groups by primary mechanism. Part 2.1 compares those groups with Canadian legal and survey categories. Part 3.1 explains what makes a treatment a psychedelic-assisted therapy, and Part 4.1 describes the routes through which such therapy can lawfully take place in Canada. HSCI 180 Lesson 7 introduced these drugs, and Lesson 3 of this course develops their pharmacology.
Learning Objectives
- 1.1 Define the classic serotonergic psychedelics and explain why psilocybin, LSD, DMT and mescaline are grouped by their shared action at the serotonin 2A receptor.
- 1.2 Distinguish entactogens, dissociatives and atypical agents from the classic psychedelics by their primary mechanism, using MDMA, ketamine, ibogaine and salvinorin A as examples.
- 2.1 Explain why pharmacological groups, Canadian legal schedules and survey categories sort the same drugs in different ways.
- 3.1 Describe the phases of psychedelic-assisted therapy and explain how this model of treatment differs from a daily medication and from supervised esketamine.
- 4.1 Identify the authorized routes through which psychedelic-assisted therapy with a controlled substance can lawfully take place in Canada as of October 2026.
1.1 What Counts as a Psychedelic
The word psychedelic has a narrow meaning, used in pharmacology, and a broad one, used in clinics, newspapers and everyday speech. Both meanings appear in the research literature, so a careful reader checks which one an author intends.
The term comes from the Greek for “mind manifesting”, and it refers to the drugs’ subjective effects. The psychiatrist Humphry Osmond proposed it in 1956, in correspondence with the writer Aldous Huxley, and introduced it publicly in a medical paper in 1957 (Kelmendi et al., 2022; Dyck, 2019). Lesson 2 describes how the word entered psychiatry during the first period of psychedelic research.
1.1.1 The Narrow Definition: Classic Serotonergic Psychedelics
In its narrow sense, the word refers to the classic, or serotonergic, psychedelics. David Nichols (2016) describes them as powerful psychoactive substances that alter perception and mood and affect numerous cognitive processes, and he reports a consensus that they act as agonists or partial agonists at the serotonin 2A receptor, usually written as the 5-HT2A receptor. An agonist is a molecule that binds to a receptor and activates it, much as the body’s own neurotransmitter would, and a partial agonist activates it less fully. The receptors that matter most sit on the long upper branches (apical dendrites) of pyramidal neurons in layer V of the neocortex (Nichols, 2016). Kelmendi and colleagues (2022) state that 5-HT2A receptors are essential for the subjective effects of these drugs. The two reviews agree on this account of the class, which Nichols describes as a consensus.
The classic psychedelics come from three chemical families (Kelmendi et al., 2022). The tryptamines, whose structure resembles serotonin itself, include psilocybin, its active metabolite psilocin, and N,N-dimethyltryptamine (DMT). The ergolines, made by chemically processing compounds first isolated from the ergot fungus, include lysergic acid diethylamide (LSD). The phenethylamines, built on a different scaffold of a benzene ring and a short amine chain, include mescaline. The three families look different on paper, yet all of them act through the same receptor, which is why researchers treat them as one pharmacological class. 3-D Model 1.1 lets you explore where this shared receptor is concentrated in the adult human brain, using a group-average map from positron emission tomography (PET), a scanning method that follows a weakly radioactive tracer that binds to the receptor.
1.1.2 The Broad Definition: Atypical Compounds
Several other drugs produce related psychological effects through different mechanisms. Kelmendi and colleagues (2022) call them atypical compounds and note that they are sometimes called psychedelics under a broader definition. The group includes MDMA, a phenethylamine that binds weakly or not at all to serotonin receptors, and a set of drugs the same authors call dissociatives: ketamine, phencyclidine (PCP), nitrous oxide, ibogaine and salvinorin A. Other authors sort these drugs differently: Mosca and colleagues (2023) describe ibogaine as a psychedelic with dissociative properties. This course places ketamine among the dissociatives and treats ibogaine and salvinorin A as a separate group of atypical agents, because each acts mainly through targets that neither the classic psychedelics nor ketamine share.
1.1.3 Other Words for the Same Drugs
The vocabulary is crowded because each word emphasizes a different part of the experience. Kelmendi and colleagues (2022) note that “hallucinogen” emphasizes perceptual effects, “entheogen” spiritual effects, and “empathogen” or “entactogen” social and emotional effects. Two further conventions apply in this course. The word hallucinogen is used only as a legal or survey category, since, as Section 3 shows, one Canadian survey’s hallucinogen category included the dissociative PCP alongside LSD and psilocybin. The phrase plant medicines is used only when describing how communities name their own ceremonial practices with plants such as peyote or ayahuasca.
The six cards below define the terms that recur most often; note which feature of the drug or experience each term picks out.
Part 1.1 has distinguished a narrow class defined by one receptor from a broad family defined by similar experiences. Part 1.2 turns these definitions into four working groups, and Part 2.1 compares them with the ways Canadian law and Canadian surveys sort the same drugs.
1.2 Four Groups of Substances
For most purposes in this course, the substances fall into four groups: the classic psychedelics, the entactogen MDMA, the dissociative ketamine, and the atypical agents ibogaine and salvinorin A. Grouping by primary mechanism makes the later lessons easier to follow, because mechanism shapes effects, risks and drug interactions.
Table 1.1 lists eight substances with their natural source or origin, their group, their primary mechanism and their status under the Controlled Drugs and Substances Act (CDSA), Canada’s main drug control statute. Figure 1.1 then shows the four primary molecular targets side by side.
Table 1.1. Eight substances discussed in this course, with their source, group, primary mechanism and status under the Controlled Drugs and Substances Act as consolidated to 30 September 2026.
| Substance | Source or origin | Group | Primary mechanism | Status in Canada |
|---|---|---|---|---|
| Psilocybin and psilocin | A few hundred species of mushrooms (Kelmendi et al., 2022) | Classic psychedelic (tryptamine) | Psilocybin is a prodrug converted to psilocin in the gut lining and liver; psilocin activates 5-HT2A receptors | CDSA Schedule III |
| LSD | Made from compounds first isolated from the ergot fungus | Classic psychedelic (ergoline) | Activates 5-HT2A receptors | CDSA Schedule III |
| DMT | Many plants; a component of the Amazonian brew ayahuasca | Classic psychedelic (tryptamine) | Activates 5-HT2A receptors; inactive when swallowed unless monoamine oxidase is inhibited | CDSA Schedule III |
| Mescaline | Peyote and San Pedro cacti (Kelmendi et al., 2022) | Classic psychedelic (phenethylamine) | Activates 5-HT2A receptors | CDSA Schedule III, with the entry reading “but not peyote” |
| MDMA | Synthetic | Entactogen | Carried into neurons by the serotonin transporter, which then releases stored serotonin (Nichols, 2022) | CDSA Schedule I, listed among the amphetamines |
| Ketamine | Synthetic anaesthetic in clinical use since 1970 (Zanos et al., 2018) | Dissociative | Inhibits NMDA glutamate receptors (Zanos et al., 2018) | CDSA Schedule I, listed under phencyclidine and its derivatives |
| Ibogaine | Root of the West African shrub Tabernanthe iboga, a sacrament in the Bwiti religion (Mosca et al., 2023) | Atypical agent | Many targets, including monoamine transporters and NMDA, nicotinic and 5-HT2A receptors; its metabolite noribogaine activates kappa-opioid receptors (Mosca et al., 2023) | Outside the CDSA; added to Health Canada’s Prescription Drug List on 19 May 2017 |
| Salvinorin A | Leaves of Salvia divinorum, used in Mazatec spiritual practice in Oaxaca, Mexico (Roth et al., 2002) | Atypical agent | Selective kappa-opioid receptor agonist with no action at 5-HT2A receptors (Roth et al., 2002) | CDSA Schedule IV (Salvia divinorum and its preparations, in force from February 2016) |
Two entries need comment. Psilocybin is a prodrug, a compound that becomes active only after the body converts it (Kelmendi et al., 2022), so studies of psilocybin are in practice studies of psilocin; Lesson 3 explains this and the pharmacology of ayahuasca. Ibogaine was added to the Prescription Drug List after Health Canada received reports of serious adverse reactions, so that its sale could be restricted to prescription (Health Canada, 2017); Lesson 6 examines its cardiac risks.
Interactive 1.1 asks you to sort the eight substances yourself. For each one, choose its group and its primary mechanism, then check your answers against Table 1.1 and the feedback, which gives the source for each placement.
Sort substances by group and primary mechanism
2.1 Legal Schedules and Survey Categories Sort the Same Drugs Differently
Pharmacological groups are only one way of sorting these drugs, and Canadian law and Canadian surveys use others. The CDSA does not follow pharmacology: as of October 2026, its consolidated text places the classic psychedelics in Schedule III, while MDMA and ketamine sit in Schedule I, the schedule that also holds heroin and fentanyl. Salvia divinorum was added to Schedule IV by an order published in August 2015, the mescaline entry excludes peyote, and ibogaine is not listed at all. Schedule placement affects penalties and the conditions for research, so a drug’s legal category can matter more to a trial than its mechanism. HSCI 180 Lessons 11 and 12 explain how schedules were built.
National surveys use a third system, built around how respondents describe what they took. Health Canada’s Canadian Alcohol and Drugs Survey of 2019 defined hallucinogens as drugs such as LSD, PCP and psilocybin, and asked about salvia as a separate drug (Health Canada, 2021). The Canadian Substance Use Survey of 2025 asks separately about psychedelics, a category that includes salvia, and about dissociatives such as ketamine and PCP (Health Canada, 2026b). PCP is pharmacologically unlike LSD, yet the 2019 survey counted the two together, and the salvinorin A in salvia is pharmacologically unlike psilocybin, yet the 2025 survey counts those two together. Section 3 shows why these choices matter when survey estimates are compared across years.
Take ketamine and salvinorin A in turn. For each, write down its pharmacological group from Table 1.1, its CDSA schedule, and the category in which the 2019 and 2025 Canadian surveys would have counted it. Then identify one practical consequence of each kind of sorting: for a clinician choosing a monitoring plan, for a researcher applying to run a trial, and for an epidemiologist comparing survey years.
Ketamine is a dissociative (NMDA receptor inhibition), sits in CDSA Schedule I, and is counted among dissociatives in the 2025 survey. Salvinorin A is an atypical agent (kappa-opioid agonism), Salvia divinorum is in Schedule IV, and salvia was asked about separately from hallucinogens in the 2019 survey and counted among psychedelics in the 2025 survey. Mechanism guides a clinician’s monitoring plan, the schedule determines the licences a trial needs, and the survey category determines whether a change between years reflects behaviour or a change in which drugs were counted.
Part 2.1 has shown that a single drug can belong to three categories at once. Part 3.1 turns from the drugs to the treatment, and asks what turns the administration of one of these substances into a psychedelic-assisted therapy.
3.1 What Makes a Therapy Psychedelic-Assisted
Psychedelic-assisted therapy (PAT) is a structured psychotherapeutic process in which a person receives one or a few supervised doses of a psychedelic within a course of screening, preparation and integration. The therapy and the therapeutic relationship are part of the treatment, and this course treats them as such. The terms psilocybin-assisted therapy, MDMA-assisted therapy and ketamine-assisted psychotherapy name the same model with a particular drug.
3.1.1 A Process with Phases
The clearest way to see the model is to look at a published protocol. In the phase 3 trial of MDMA-assisted therapy for post-traumatic stress disorder reported by Mitchell and colleagues (2021), participants first completed screening and tapered off their psychiatric medications under supervision. They then attended three preparatory sessions, three eight-hour experimental sessions spaced about four weeks apart, and nine 90-minute integration sessions, all within about 18 weeks. The first integration session took place on the morning after each experimental session. Participants randomized to placebo received the same therapy with an inactive pill, so the trial compared MDMA plus therapy with the same therapy given with placebo.
Other trials weight the phases differently. Kelmendi and colleagues (2022) observe that one or two trained facilitators are usually present during dosing, that depression trials provide support mainly during dosing with a few integration sessions, and that trials for substance use disorders embed dosing in a multi-week course of psychotherapy. Lesson 7 examines these models, including group programs in British Columbia.
3.1.2 How This Differs from a Daily Medication
A daily medication is taken on a fixed schedule, usually at home and often for months. A trial reported by Carhart-Harris and colleagues (2021) makes the contrast concrete. Fifty-nine adults with moderate to severe major depressive disorder received either two 25 mg doses of psilocybin three weeks apart plus six weeks of daily placebo capsules, or two 1 mg doses of psilocybin plus six weeks of daily escitalopram, a selective serotonin reuptake inhibitor. Every participant received psychological support. One arm therefore took its active drug on two days, and the other took its active drug on about 42 days. In a phase 2 trial for treatment-resistant depression, Goodwin and colleagues (2022) gave a single dose of a synthetic psilocybin formulation (25 mg, 10 mg or 1 mg) with psychological support. Figure 1.2 sets these schedules side by side.
The difference in schedule brings other differences with it. Drug sessions take place in a clinic with trained staff present for many hours, and the intense acute experience is worked with in preparation and integration, so supervision and psychological work are part of the treatment. The risks are concentrated in a few days, so screening and monitoring carry much of the safety burden (Lesson 6). Any lasting benefit must persist long after the drug has left the body, which is why Lessons 8 to 10 attend closely to the length of follow-up.
Esketamine shows that the boundary between the two models is not always sharp. The United States Food and Drug Administration (FDA) approved the esketamine nasal spray Spravato on 5 March 2019 for adults with treatment-resistant depression, in combination with an oral antidepressant, under a restricted distribution program: patients take the spray under the supervision of a health care provider in a certified office or clinic and cannot take it home (FDA, 2019). Health Canada first authorized it in May 2020 for adults who had not responded to at least two antidepressants, also in combination with an antidepressant (Janssen Inc., 2021). The drug is given repeatedly under supervision without built-in psychotherapy. The three tabs below summarize the three arrangements.
The person takes a fixed dose every day, usually at home, for weeks or months, and any psychotherapy is a separate treatment. The daily escitalopram arm follows this model (Carhart-Harris et al., 2021).
The person receives one to three doses, each in a long supervised session, within a course of screening, preparation and integration, and the therapeutic relationship is part of the treatment. The MDMA protocol in Figure 1.2 follows this model (Mitchell et al., 2021).
The person takes an approved drug repeatedly under supervision in a certified clinic, with a daily oral antidepressant, and psychotherapy is not part of the approved product (FDA, 2019). Ketamine-assisted psychotherapy, which adds structured therapy, is discussed in Lesson 8.
4.1 Where Psychedelic-Assisted Therapy Is Lawful in Canada
The same drug can be part of a lawful treatment or of an offence, depending on the route by which it is obtained and given. The box below summarizes Health Canada’s description, and Lesson 11 examines each route.
Lawful routes for psychedelic-assisted therapy in Canada (as of October 2026)
Health Canada’s public page on psilocybin, last modified on 8 October 2025, states that the production, sale and possession of magic mushrooms are illegal in Canada. It names three pathways for authorized access: clinical trials, the Special Access Program, and individual exemptions under subsection 56(1) of the CDSA. The same page states that no therapeutic product containing psilocybin had been approved in Canada or elsewhere (Health Canada, 2025).
Since 1 October 2026, the Special Access Program route for restricted drugs such as psilocybin and MDMA has been governed by the Controlled Substances Regulations (SOR/2025-242), which allow a practitioner named in a Special Access Program letter of authorization to administer or provide the drug. These regulations replaced Part J of the Food and Drug Regulations and other older regulations. They also absorbed the subsection 56(1) class exemption that Health Canada had issued for psilocybin and MDMA after amendments in January 2022 restored access to restricted drugs through the program (Canada Gazette, 2025). Lesson 11 describes this history.
Because psilocybin, MDMA and LSD are scheduled substances, section 4 of the CDSA makes it an offence to possess them except as authorized under the regulations, and section 21 of the Criminal Code makes anyone who aids or abets an offence a party to it. A regulated professional who gives preparation or integration support for unauthorized use may therefore be at legal risk. Lessons 7 and 11 explain this position as a matter of law; it is not legal advice for any individual situation.
Each of these routes authorizes a specific person to receive a specific drug under specific conditions, and psychedelic-assisted therapy supplies the screening, supervision and integration that those conditions assume. Case 1.1 shows the same molecule without that structure.
In the phase 2 trial of Goodwin and colleagues (2022), adults with treatment-resistant depression were screened, received a single dose of a synthetic psilocybin formulation with psychological support, and were followed for 12 weeks with standardized ratings. In May 2024, Matsukubo and colleagues (2025) identified 57 unlicensed psilocybin dispensaries in Canada. Almost all of the stores they examined sold dried mushrooms and microdosing capsules, most sold psilocybin chocolate and gummies, and 86.4 percent of the dispensary websites claimed mental health benefits, such as relief of anxiety. The authors noted that the websites very rarely mentioned that the benefits reported in trials came from psychedelic-assisted therapy.
The molecule is the same in both settings, while the dose, screening, support, follow-up and evidence differ. Section 3 returns to these storefronts, and Section 4 asks how to judge their claims.
Summary
This section defined the classic psychedelics by their shared action at the 5-HT2A receptor and placed MDMA, ketamine, ibogaine and salvinorin A in separate groups by primary mechanism. Canadian law and Canadian surveys sort the same drugs in other ways, so a reader must ask which system a source uses. Psychedelic-assisted therapy is a phased process of screening, preparation, one or a few supervised dosing sessions and integration, distinct from daily medication and from supervised esketamine, and in Canada, as of October 2026, it can take place lawfully only through the routes described in Part 4.1.
Section 2 turns to the experiences these drugs produce. It asks how researchers measure perceptual, emotional, cognitive and self-related changes, how user-reported sources describe them, and what each kind of source can and cannot establish.
Key Takeaways
- 1.1 In its narrow, pharmacological sense, a psychedelic is a classic serotonergic psychedelic: a drug that acts as an agonist or partial agonist at serotonin 2A (5-HT2A) receptors. Psilocybin, LSD, DMT and mescaline come from three chemical families (tryptamines, ergolines and phenethylamines), yet they form one class because they act through the same receptor. Words such as hallucinogen, entheogen and entactogen each emphasize a different part of the experience, so a careful reader checks which meaning an author intends.
- 1.2 MDMA, ketamine, ibogaine and salvinorin A produce related experiences through different primary mechanisms. MDMA, the entactogen, is carried into neurons by the serotonin transporter and releases serotonin; ketamine, the dissociative, inhibits NMDA glutamate receptors; salvinorin A is a selective kappa-opioid agonist, and ibogaine acts at many targets. Because mechanism shapes effects, risks and drug interactions, findings about one drug cannot be transferred to the others.
- 2.1 The Controlled Drugs and Substances Act does not follow pharmacology: as of October 2026, the classic psychedelics sit in Schedule III, MDMA and ketamine in Schedule I, salvia in Schedule IV, and ibogaine outside the Act. National surveys use a third system, so the 2019 survey counted PCP with LSD and psilocybin, and the 2025 survey counts salvia with psychedelics. A reader must ask which system a source uses, because each kind of sorting matters to a different decision.
- 3.1 Psychedelic-assisted therapy places one or a few supervised dosing sessions inside a course of screening, preparation and integration, as in the MDMA protocol of Mitchell and colleagues (2021). In the trial of Carhart-Harris and colleagues (2021), the psilocybin arm took its active drug on two days and the escitalopram arm on about 42 days. Supervised esketamine sits between the two models: it is given repeatedly in a certified clinic without built-in psychotherapy.
- 4.1 As of October 2026, Health Canada names three authorized routes for psychedelic-assisted therapy with a controlled substance: clinical trials, the Special Access Program and subsection 56(1) exemptions. Since 1 October 2026 the Special Access Program route has been governed by the Controlled Substances Regulations. Outside these routes, possession is an offence, and the same molecule sold in a storefront comes without the screening, support and follow-up that trials provide.
Reflection
A hypothetical news article describes psilocybin, MDMA, ketamine and ibogaine as “psychedelics that all work the same way” and suggests that a person could “take them at home like an antidepressant.” Use these facts to write a correction of 150 to 250 words. Psilocybin is converted to psilocin, which activates serotonin 2A (5-HT2A) receptors. MDMA is carried into neurons by the serotonin transporter, which then releases stored serotonin. Ketamine inhibits NMDA glutamate receptors. Ibogaine acts at many targets, including monoamine transporters and NMDA and nicotinic receptors, and its metabolite noribogaine activates kappa-opioid receptors. In one trial, one group received two 25 mg doses of psilocybin three weeks apart with psychological support, while the other took escitalopram every day for six weeks (Carhart-Harris et al., 2021). In an MDMA trial, participants attended three preparatory sessions, three eight-hour experimental sessions and nine integration sessions over about 18 weeks (Mitchell et al., 2021). As of October 2026, psilocybin and MDMA are scheduled under Canada’s Controlled Drugs and Substances Act, and Health Canada names clinical trials, the Special Access Program and subsection 56(1) exemptions as the authorized routes. Explain (a) why grouping the four drugs as working “the same way” is misleading, and (b) how psychedelic-assisted therapy differs from taking a daily medication, including where it can lawfully take place in Canada.
The four drugs produce some overlapping experiences, yet they act through different targets. Psilocybin works through psilocin, which activates serotonin 2A receptors, the defining action of the classic psychedelics. MDMA is an entactogen: the serotonin transporter carries it into neurons, and stored serotonin is released. Ketamine is a dissociative that inhibits NMDA glutamate receptors, and ibogaine acts at many targets at once, with a metabolite that activates kappa-opioid receptors. Because mechanism shapes effects, risks and drug interactions, a claim about one of these drugs cannot be transferred to the others.
The comparison with an antidepressant is also misleading. In the trial by Carhart-Harris and colleagues, the escitalopram group took a pill on about 42 days, while the psilocybin group took the active drug on two days, each time with psychological support. The MDMA protocol of Mitchell and colleagues placed three supervised eight-hour sessions inside a course of three preparatory and nine integration sessions. Supervision, preparation and integration are part of the treatment, which is why psychedelic-assisted therapy is delivered in clinics with trained staff. As of October 2026, psilocybin and MDMA can lawfully be given for therapy in Canada only through a clinical trial, the Special Access Program or a subsection 56(1) exemption.
Minimum 20 characters required.
Question 1: What feature defines the classic psychedelics as a pharmacological class?
Question 2: Which statement about MDMA is consistent with Nichols (2022)?
Question 3: In the trial reported by Carhart-Harris and colleagues (2021), how did dosing in the psilocybin arm differ from dosing in the escitalopram arm?
Question 4: According to Health Canada’s psilocybin page (modified in October 2025), which of the following is an authorized route of access to psilocybin?
Subjective Effects: Research Scales, User-Reported Sources and What Each Can Establish
Introduction
Psychedelics are defined by what they do to experience, so any account of them depends on how experience is described. Researchers rate experiences on standardized questionnaires, interview people about what happened to them, and analyze large collections of written reports. People who use psychedelics, for their part, have built their own vocabularies and reference works, and clients bring that vocabulary into clinics. Each kind of source answers some questions well and others poorly.
Part 5.1 describes four domains of change that recur across sources. Part 5.2 explains four research scales, and Part 5.3 works through the scoring rule of one of them with a calculator. Part 6.1 considers what research scales can and cannot establish, Part 6.2 describes three user-reported or user-facing resources and the research that has drawn on them, and Part 6.3 compares the three kinds of source. Lesson 5 later asks how the experience relates to therapeutic outcomes and to blinding; this section concerns description and measurement.
Learning Objectives
- 5.1 Describe the perceptual, emotional, cognitive and self-related changes that psychedelics produce, using the vocabulary of research scales.
- 5.2 Explain the structure and scoring of the 5D-ASC, the MEQ30, the Ego Dissolution Inventory and the Challenging Experience Questionnaire.
- 5.3 Calculate whether a set of MEQ30 factor scores meets the research criterion for a “complete mystical experience”, and explain the limits of that threshold.
- 6.1 Explain what research scales can and cannot establish about psychedelic experiences, given how they were built and validated.
- 6.2 Describe PsychonautWiki’s Subjective Effect Index, Erowid’s Experience Vaults and TripSit as user-reported or user-facing sources, and state what such sources can and cannot establish.
- 6.3 Compare what research scales, qualitative studies and user-reported sources can and cannot establish about psychedelic experiences.
5.1 Four Domains of Subjective Change
Preller and Vollenweider (2018) describe the state produced by classic psychedelics as an altered state of consciousness marked by profound changes in sensory perception, mood, thought (including the perception of reality) and the sense of self. This course groups these changes into four domains: perceptual, emotional, cognitive and self-related.
The four tabs below describe each domain, using the names of the lower-order scales that Studerus, Gamma and Vollenweider (2010) derived from a standard research questionnaire, and the corresponding headings in PsychonautWiki’s user-contributed Subjective Effect Index (PsychonautWiki, 2026).
Perceptual changes include elementary imagery (patterns, colours and lights, often with the eyes closed), complex imagery (scenes and figures), audio-visual synesthesia (sounds that change what is seen) and a changed meaning of percepts, in which ordinary objects seem significant (Studerus et al., 2010). Kelmendi and colleagues (2022) describe perceptual alterations akin to visual hallucinations, illusions and synesthesia. PsychonautWiki lists visual effects under the subheadings amplifications, suppressions, distortions, geometry and hallucinatory states, with further headings for auditory, tactile and multisensory effects.
Emotional changes range from a blissful state of deep positive mood to anxiety (Studerus et al., 2010). Kelmendi and colleagues (2022) note that psilocybin can induce anxiety and distressing effects, including a dread of ego dissolution. Research and clinical writing calls an episode of intense fear, grief or distress a challenging experience; people who use psychedelics often call it a “bad trip”. Lesson 5 examines how often such experiences occur and how people make meaning of them.
Cognitive changes include insightfulness, a sense of new understanding about oneself or one’s life, and impaired control and cognition, such as difficulty directing thought (Studerus et al., 2010). Changes in the perception of time are also common (Preller & Vollenweider, 2018). PsychonautWiki divides cognitive effects into enhancements, depressions, intensifications, suppressions, novel, psychological and transpersonal effects, and lists thought loops and time distortion among the novel effects.
Self-related changes include an experience of unity with one’s surroundings, disembodiment and spiritual experience (Studerus et al., 2010). Ego dissolution, a temporary loss of the usual sense of being a separate self, is described by Nour and colleagues (2016) as a key feature of the psychedelic experience. Kelmendi and colleagues (2022) report that psilocybin increases feelings of unity and of transcendence of time and space. PsychonautWiki lists ego dissolution and unity under “transpersonal”, a subheading of its cognitive effects.
Two further points apply across the domains. The first is that the state changes over time: Preller and Vollenweider (2018) describe people progressing through stages during a session, along a continuum from perceptual change towards hallucination with increasing arousal and ego dissolution. The second is that profiles differ between drugs. In data pooled by Studerus and colleagues (2010), sessions with psilocybin scored much higher than sessions with MDMA on elementary imagery, and sessions with ketamine scored higher than MDMA sessions on disembodiment and lower on blissful state. These differences fit the separate groups in Section 1: the drugs share a family resemblance in experience while differing in mechanism.
The domains give a vocabulary, but a vocabulary does not measure anything. Part 5.2 explains how researchers turn these descriptions into numbers that can be compared across people, doses and drugs.
5.2 Measuring the Experience with Research Scales
A research scale is a fixed set of questionnaire items, each rated on a defined response format, that has been tested for reliability and validity in a stated population. Scales make experiences comparable, and their limits come from the same source as their strengths: the researchers decide in advance what will be asked.
5.2.1 The 5D-ASC
In a 2024 review of 93 trials of classic psychedelics, Hovmand and colleagues (2024) found that the 5D-ASC described below was the rating scale used most often. It belongs to a family of questionnaires for altered states that began with Dittrich’s APZ, which had 158 yes-or-no items; its revision, the OAV, has 66 items rated on visual analogue scales, horizontal lines on which the respondent marks a point between “no, not more than usual” and “yes, very much more than usual”, scored from 0 to 100 (Studerus et al., 2010). The OAV measures three primary dimensions: oceanic boundlessness, a positively experienced loss of boundaries similar to mystical experience; dread of ego dissolution, a negatively experienced loss of self with cognitive disturbance and loss of control; and visionary restructuralization, which covers imagery and changed meaning. An extended version published in 1999, the five-dimensional altered states of consciousness questionnaire (5D-ASC), adds 16 items on auditory alterations and 12 on vigilance reduction, for 94 items in all.
Studerus and colleagues (2010) tested the structure of the OAV using 591 drug sessions pooled from 43 experimental studies with healthy volunteers in Zurich between 1992 and 2008: 327 psilocybin sessions, 162 ketamine sessions and 102 MDMA sessions. The original three dimensions turned out to combine several distinct experiences, so the authors derived 11 more specific lower-order scales with good psychometric properties that differentiated well among the three drugs. Figure 1.3 shows how the scales relate to the original dimensions.
5.2.2 The Mystical Experience Questionnaire (MEQ30)
The Mystical Experience Questionnaire grew from a philosophical account of mysticism. Following an account of mysticism by W. T. Stace (1960), as described by Barrett and colleagues (2015), it treats a mystical experience as combining unity, a felt sense of sacredness, a sense of encountering truth (noetic quality), deeply felt positive mood, transcendence of time and space, and difficulty describing the experience in words (ineffability). The earlier 43-item version had seven subscales; the revised 30-item version, the MEQ30, reduces them to four factors: mystical (unity, noetic quality and sacredness), positive mood, transcendence of time and space, and ineffability. Each item is rated from 0 (“none; not at all”) to 5 (“extreme”) (Barrett et al., 2015).
5.2.3 Ego Dissolution and Challenging Experiences
Two shorter or more specialized scales complete the set used in this course. Nour and colleagues (2016) developed the Ego Dissolution Inventory (EDI), an 8-item scale rated on visual analogue lines. In an internet survey of 691 people describing 1,828 drug experiences, EDI scores rose with dose for psychedelics, but not for cocaine or alcohol, which supported the claim that ego dissolution is specific to psychedelic states. Barrett and colleagues (2016) developed the Challenging Experience Questionnaire (CEQ) from an internet survey of difficult experiences with psilocybin mushrooms; its 26 items form seven factors: grief, fear, death, insanity, isolation, physical distress and paranoia. Lesson 5 uses the CEQ to examine how often challenging experiences occur. Table 1.2 summarizes the four instruments.
Table 1.2. Four research scales for psychedelic experiences, with their structure, response format and development sample.
| Scale | What it measures | Structure and format | Development or validation sample |
|---|---|---|---|
| 5D-ASC (Studerus et al., 2010) | Altered states of consciousness from any cause | 94 items on 0 to 100 visual analogue scales; 5 dimensions and 11 lower-order scales | 591 laboratory sessions with psilocybin, ketamine or MDMA in healthy volunteers, Zurich, 1992 to 2008 |
| MEQ30 (Barrett et al., 2015) | Mystical-type experience | 30 items rated 0 to 5; 4 factors; “complete” when every factor is at least 60 percent of the maximum | 184 participants given psilocybin in five laboratory studies at Johns Hopkins University |
| EDI (Nour et al., 2016) | Ego dissolution | 8 items on visual analogue scales; one factor | Internet survey of 691 people describing 1,828 experiences with psychedelics, cocaine or alcohol |
| CEQ (Barrett et al., 2016) | Challenging experiences | 26 items; 7 factors | Internet survey of people describing a difficult experience with psilocybin mushrooms |
5.3 The Complete Mystical Experience Criterion
One feature of the MEQ30 needs closer attention, because it turns a profile of scores into a single yes-or-no outcome that trials often report.
Barrett, Johnson and Griffiths (2015) validated the MEQ30 with data pooled from five laboratory studies approved by the Johns Hopkins University School of Medicine in which 184 participants received a moderate to high oral dose of psilocybin and completed the questionnaire about seven hours after taking the capsule. Scores on the mystical factor predicted participants’ later ratings of the spiritual significance of the session and of positive changes in behaviour they attributed to it. The authors also adapted a dichotomous rule from the earlier version: a session counts as a complete mystical experience when the score on every one of the four factors is at least 60 percent of the maximum possible score. Under this rule, 94 of the 184 sessions (51 percent) qualified.
Equation 1.1 gives the calculation for one factor. Because every item has a maximum of 5, the percentage of the maximum equals the mean item score divided by 5.
Worked example. Suppose a hypothetical participant’s mean item scores are 3.6 on the mystical factor, 3.2 on positive mood, 3.9 on transcendence of time and space and 2.8 on ineffability. The percentages are 3.6 ÷ 5 × 100 = 72, 3.2 ÷ 5 × 100 = 64, 3.9 ÷ 5 × 100 = 78 and 2.8 ÷ 5 × 100 = 56. Three factors pass the 60 percent threshold and ineffability does not, so the session does not meet the criterion, even though its average across the four factors is 67.5 percent. Use Calculator 1.1 to try other profiles, and notice that one low factor decides the classification however high the others are.
The rule is a research convention. It turns a continuous profile into a yes-or-no category, which is convenient for reporting the share of participants who had a complete experience, and it discards information, since a participant at 59 percent on one factor is classified with one at 10 percent.
6.1 What Research Scales Can and Cannot Establish
What these scales can establish follows from how they were built. Because every respondent answers the same items, scales can show how experience changes with dose, how drugs differ, and whether features of the acute experience predict later outcomes. Their limits follow from the same design. The ratings are retrospective, made hours or years after the experience. The items reflect theories chosen by researchers, such as Stace’s account of mysticism, which comes from one philosophical and religious tradition. The development samples in Table 1.2 were mostly healthy or screened volunteers in laboratories and self-selected internet respondents, who may differ from patients in trials, and a 2023 scoping review by Herrmann and colleagues (2023) noted that the samples used for such scales are often small and self-selected. Part 6.2 turns to sources in which people describe their experiences in their own words.
6.2 User-Reported Sources
Most people who use psychedelics never take part in a study, and they have built their own resources for describing what happens. Clients in psychedelic-assisted therapy often arrive having read them. The three resources below are user-contributed or user-facing; this course cites them for what people who use psychedelics report and for the harm reduction information they publish, and never as evidence that a drug is effective or safe.
PsychonautWiki describes its Subjective Effect Index as a collection of wiki articles intended as a comprehensive reference work on the effects of psychoactive substances, and hopes its definitions will become a universal terminology. Its articles use a formalized style that avoids metaphor, and each entry gives a name, a description of the experience and related information. The site states that its content is derived principally from the collective experiences and analyses of its contributors, from anecdotal reports collected on the internet and, whenever possible, from published scientific literature (PsychonautWiki, 2026). Its top-level headings are visual, auditory, tactile, disconnective, smell and taste, multisensory, cognitive, physical and uncomfortable physical effects. The site also publishes dosage and interaction pages written from user reports, which this course does not reproduce.
Erowid describes itself as a member-supported organization that provides reliable, non-judgemental information about psychoactive plants, chemicals and related issues (Erowid, 2017). Its Experience Vaults hold more than 45,000 first-hand reports, which Erowid states are the writings and opinions of the people who submit them; a review team screens and sorts the submissions (Erowid, n.d.).
TripSit describes its mission as harm reduction through education. Unpaid volunteers run live chat support and publish drug factsheets that use PsychonautWiki’s Subjective Effect Index, and the site states that it is not a replacement for medical help because its volunteers are not medical professionals (TripSit, 2016).
Researchers have begun to analyze such collections at scale. Zamberlan and colleagues (2018) applied natural language processing to reports from Erowid’s Experience Vaults and found preliminary evidence that drugs with similar receptor-binding profiles were described in more similar language. Ballentine, Friedman and Bzdok (2022) analyzed word use in 6,850 free-form testimonials about 27 drugs and linked patterns of description to the distribution of 40 neurotransmitter receptor subtypes in the brain. Both studies used user reports to generate hypotheses about mechanism that laboratory studies of one drug at a time could not easily produce. These are early, exploratory studies: Zamberlan and colleagues described their evidence as preliminary, and both sets of findings remain hypotheses for laboratory research to test.
The box below sets out what this kind of source can support. Its central point is that a report describes an experience as the person understood it, without an independent check of what was taken or how often such experiences occur.
What user-reported sources can and cannot establish
User-reported sources can establish the vocabulary that people who use psychedelics use, the range of experiences they describe, including rare or unusual ones, the meanings they give to those experiences, and the harm reduction information that communities circulate. They can also generate hypotheses for research, as the studies of Erowid reports show.
They cannot establish how often an effect occurs, because there is no denominator: no one knows how many people had a similar experience and did not write about it. They cannot confirm what substance or dose was taken; in a citizen-science study of microdosing, the investigators listed the lack of verification of the nature, purity and dose of the substances as a key limitation (Szigeti et al., 2021), and Health Canada (2025) warns that illegally produced drugs are not tested. They cannot show that a drug caused an outcome, and they are never evidence that a drug is effective or safe.
User reports, then, are rich in description and weak in verification, which is nearly the reverse of research scales. Part 6.3 places them beside qualitative research and the scales to compare all three.
6.3 Comparing the Three Kinds of Source
A third kind of source lies between the scale and the online report. Qualitative studies interview participants in trials or treatment programs and analyze what they say with defined methods. Breeksema and colleagues (2020) synthesized 15 such studies covering 178 patients treated with psilocybin, LSD, ibogaine, ayahuasca, ketamine or MDMA for conditions including depression, anxiety, eating disorders, post-traumatic stress disorder and substance use disorders. Despite the different drugs and settings, patients described comparable processes, including insight, altered self-perception, increased connectedness, transcendental experiences and an expanded range of emotion.
Table 1.3 compares the three kinds of source on who reports, how the experience is captured, what is verified, and which claims each can support.
Table 1.3. Research scales, qualitative studies and user-reported sources compared.
| Feature | Research scales | Qualitative studies | User-reported sources |
|---|---|---|---|
| Who reports | Study participants, often healthy volunteers or screened patients | Participants in trials or programs, usually small groups | Self-selected writers and contributors |
| How experience is captured | Fixed items with numeric ratings | Interviews in the person’s own words, analyzed systematically | Free-form reports, edited summaries and wiki articles |
| Substance and dose verified | Yes, in laboratory and trial studies | Yes, when drawn from trials | No |
| Strongest use | Comparing doses, drugs and people; predicting later outcomes | Understanding meaning and therapeutic processes | Vocabulary, breadth of experiences, hypotheses, harm reduction information |
| Main limits | Researchers choose the items; ratings are retrospective | Small, selected samples; findings depend on the analysts | No denominator, no verification, no evidence of efficacy or safety |
For each of these hypothetical statements, decide which kind of source in Table 1.3 could best support it, and why. (a) “People who use psychedelics describe a visual effect they call tracers.” (b) “Higher doses of psilocybin produce more ego dissolution than lower doses.” (c) “Patients in a trial described feeling more connected to others after treatment.” (d) “Most people who microdose experience improved focus.”
(a) A user-reported source is the right evidence for what people who use psychedelics call an effect, and PsychonautWiki lists tracers among visual distortions. (b) A research scale, such as the EDI, given at controlled doses can test a dose-response claim; Nour and colleagues (2016) found that EDI scores rose with reported dose for psychedelics. (c) A qualitative study of trial participants can document this, as in the synthesis by Breeksema and colleagues (2020). (d) None of the sources in this section can support a claim about most people, because it requires a representative sample and a measured outcome; Section 3 shows how surveys and trials address such claims, and Section 4 shows how to judge them.
Summary
This section described four domains of subjective change (perceptual, emotional, cognitive and self-related) and showed that their profiles differ between drugs and over the course of a session. It explained the 5D-ASC, the MEQ30, the EDI and the CEQ, including the MEQ30 rule for a complete mystical experience, and noted that scales are comparable across people because researchers fix the items in advance. It described PsychonautWiki, Erowid and TripSit as user-reported or user-facing sources that are rich in vocabulary and unverified, and compared them with research scales and qualitative studies.
Section 3 moves from the experience to the people who have it. It asks how many people in Canada and the United States use psychedelics, in what forms and settings, and what surveys and studies of storefronts, microdosing and retreats can tell us about them.
Key Takeaways
- 5.1 The changes that psychedelics produce fall into four domains: perceptual (elementary and complex imagery, synesthesia, changed meaning of percepts), emotional (from blissful states to anxiety), cognitive (insightfulness, impaired control, altered time) and self-related (unity, disembodiment, ego dissolution). The state changes over the course of a session, and profiles differ between drugs, so psilocybin, MDMA and ketamine share a family resemblance in experience while differing in mechanism.
- 5.2 The 94-item 5D-ASC measures altered states from any cause on 0 to 100 visual analogue scales, with five dimensions and 11 lower-order scales. The MEQ30 rates 30 items from 0 to 5 on four factors drawn from Stace’s account of mysticism. The 8-item Ego Dissolution Inventory and the 26-item Challenging Experience Questionnaire, with seven factors, complete the set used in this course.
- 5.3 A session counts as a complete mystical experience when every one of the four MEQ30 factors reaches at least 60 percent of its maximum, which equals a mean item score of 3.0 or more on each factor. One low factor decides the classification however high the others are, and the rule discards information by treating a score of 59 percent like a score of 10 percent. It is a research convention for reporting, not a natural boundary in experience.
- 6.1 Because every respondent answers the same items, research scales can show how experience changes with dose, how drugs differ, and whether the acute experience predicts later outcomes. Their limits follow from the same design: the ratings are retrospective, the items reflect theories chosen by researchers, and the development samples were mostly healthy or screened volunteers or self-selected internet respondents.
- 6.2 PsychonautWiki, Erowid and TripSit are user-contributed or user-facing resources that document the vocabulary, range of experiences and harm reduction information that circulate among people who use psychedelics, and studies of Erowid reports have used them to generate hypotheses about mechanism. They cannot establish how often an effect occurs, confirm what substance or dose was taken, or show cause, and they are never evidence that a drug is effective or safe.
- 6.3 Research scales are strong for comparison, qualitative studies for understanding meaning and therapeutic processes, and user-reported sources for vocabulary, breadth and hypotheses. Only scales and qualitative studies drawn from trials verify substance and dose, and none of the three can support a claim about how most people respond without a representative sample and a measured outcome.
Reflection
A friend shows you two accounts of “ego dissolution”. The first is a PsychonautWiki article; the site states that its Subjective Effect Index is derived mainly from contributors’ experiences and analyses, anecdotal reports collected online and, where possible, published research. The second is a laboratory study in which 184 participants given psilocybin completed the 30-item Mystical Experience Questionnaire (MEQ30; four factors, each item rated from 0 to 5) about seven hours after dosing, and in which 94 participants met the criterion for a complete mystical experience: at least 60 percent of the maximum score on every one of the four factors (Barrett et al., 2015). In 150 to 250 words, explain what each source can and cannot establish about ego dissolution or mystical-type experience, and describe one study that would use both kinds of source together. In your answer, show whether a hypothetical participant with mean factor scores of 3.4 (mystical), 3.1 (positive mood), 3.6 (transcendence of time and space) and 2.9 (ineffability) meets the MEQ30 criterion.
The PsychonautWiki article shows how people who use psychedelics describe ego dissolution and what vocabulary they share. Because it is assembled from self-selected reports, it cannot tell us how often ego dissolution occurs, which substance or dose produced it, or whether it is harmful or helpful. The laboratory study gives a standardized measure in people whose drug and dose were known, so it can compare participants and doses and relate scores to later outcomes. Its limits are that the items were chosen by researchers following one philosophical account of mysticism, that ratings are retrospective, and that its 184 participants were screened volunteers.
For the hypothetical participant, the percentages of the maximum are 3.4 ÷ 5 × 100 = 68, 3.1 ÷ 5 × 100 = 62, 3.6 ÷ 5 × 100 = 72 and 2.9 ÷ 5 × 100 = 58. Ineffability falls below 60 percent, so the profile does not meet the criterion, although its average is 65 percent.
A combined study could first analyze a large set of user reports to identify how people describe ego dissolution, then write candidate questionnaire items in that vocabulary and test them in a trial alongside the MEQ30 and the Ego Dissolution Inventory, checking whether the new items add information that the existing scales miss.
Minimum 20 characters required.
Question 1: Under the rule adapted by Barrett and colleagues (2015), when does an MEQ30 profile count as a complete mystical experience?
Question 2: A hypothetical participant’s mean MEQ30 item scores are 4.0 (mystical), 3.5 (positive mood), 3.0 (transcendence of time and space) and 2.9 (ineffability). How is this profile classified?
Question 3: Which conclusion can a user-reported source such as PsychonautWiki’s Subjective Effect Index support?
Question 4: In the data pooled by Studerus and colleagues (2010), how did ketamine sessions differ from MDMA sessions?
Who Uses Psychedelics, and How: Surveys, Microdosing, Retreats and Storefronts
Introduction
Most psychedelic use takes place outside clinics and trials. In 2025, Health Canada estimated that about 2.6 million people in Canada aged 15 or older had used a psychedelic in the past 12 months (Health Canada, 2026a), while the trials described in later lessons enrolled participants in the hundreds. Many clients who reach practitioners first met psychedelics through a storefront, a friend, a retreat or a ceremony.
Part 7.1 explains Canada’s national survey estimates, and Part 7.2 compares them with a study of adults in the United States. Parts 7.3 to 7.5 examine microdosing, retreats and ceremonies, and unlicensed storefronts. HSCI 402 develops drug checking and other harm reduction services.
Learning Objectives
- 7.1 Describe how the Canadian Substance Use Survey measures psychedelic use, and interpret its 2023 and 2025 estimates with their confidence intervals and questionnaire changes.
- 7.2 Compare Canadian survey estimates with Monitoring the Future estimates for adults in the United States, and explain why the two cannot be compared directly.
- 7.3 Summarize what population surveys, observational studies and a placebo-controlled citizen-science study show about microdosing.
- 7.4 Describe what surveys of retreat and ceremony participants report about substances, settings and adverse effects.
- 7.5 Describe the growth of unlicensed psilocybin storefronts in Canada between 2024 and 2025, the health claims they make, and Health Canada’s stated position.
7.1 Measuring Psychedelic Use in Canada
National estimates of drug use come from population surveys, which ask a sample of people about their own use and then weight the answers to represent the population. Every estimate depends on who was asked, how the question was worded and how the drugs were grouped.
7.1.1 The Canadian Substance Use Survey
As of 2026, the Canadian Substance Use Survey (CSUS) is conducted every other year by Health Canada among people aged 15 and older in the ten provinces. It replaced the Canadian Alcohol and Drugs Survey (CADS), last conducted in 2019. The 2025 cycle collected data from 7 January 2025 to 5 January 2026 and obtained 36,061 respondents, weighted to represent 34.9 million people (Health Canada, 2026a). Recruitment used random digit dialling: more than 1.2 million telephone numbers were called, and 114,373 people agreed to receive a link to the survey. Because no list connects telephone numbers to people, Health Canada cannot adjust the results for non-response, and it warns that the margins of error may therefore appear smaller than they really are. To compensate, it treated a difference between years as real only when the confidence intervals did not overlap and other evidence supported it (Health Canada, 2026a).
The box below defines the terms needed to read the estimates that follow.
Reading a survey estimate
Past-year prevalence is the percentage of the population who report any use in the 12 months before the survey; lifetime prevalence is the percentage who report ever having used. A 95 percent confidence interval gives the range of values compatible with the data under the survey’s sampling assumptions; an estimate of 7.4 percent with an interval of 7.1 to 7.8 is more precise than one of 17.2 percent with an interval of 13.7 to 21.4, which comes from a much smaller subgroup. Weighting adjusts the sample so that its distribution by province, age and sex matches the population. Survey estimates also rest on self-report and on the categories in the questionnaire, so a change in wording can change the estimate without any change in behaviour.
Table 1.4 brings together the Canadian estimates for 2019, 2023 and 2025 and the United States estimates discussed in Part 7.2. The category names in the second column matter as much as the numbers.
Table 1.4. Past-year use of psychedelics or hallucinogens in Canadian and United States surveys, with the category each survey used.
| Survey and year | Category as defined by the survey | Past-year use |
|---|---|---|
| CADS 2019 (10,293 respondents aged 15+) | Hallucinogens: drugs such as LSD, PCP and psilocybin, with salvia asked about separately | 2 percent overall; 6 percent at ages 20 to 24 |
| CSUS 2023 (36,180 respondents) | Psychedelics, asked as one grouped category (LSD, magic mushrooms or psilocybin, mescaline, peyote, 2C drugs or NBOMes) | 6 percent overall; 12 percent at ages 15 to 24 |
| CSUS 2025 (36,061 respondents) | Any psychedelic: psilocybin; LSD, mescaline, DMT, salvia, 2C drugs or NBOMes; analogues of LSD, psilocybin or DMT, asked separately | 7.4 percent overall (95 percent CI 7.1 to 7.8); psilocybin 7.2 percent; the LSD, mescaline, DMT and salvia group 1.4 percent; analogues 0.4 percent |
| Monitoring the Future, United States, 2022 | Hallucinogens; types reported included LSD, MDMA, mescaline, peyote, psilocybin and PCP | 8 percent at ages 19 to 30; 4 percent at ages 35 to 50 |
| Monitoring the Future, United States, 2023 | Hallucinogens; types reported included LSD, mescaline, peyote, psilocybin and PCP | 9 percent at ages 19 to 30; 4 percent at ages 35 to 50 |
Sources: Health Canada (2021, 2024a, 2026a, 2026b); National Institute on Drug Abuse (2023); University of Michigan (2024). CI, confidence interval.
7.1.2 What the Canadian Estimates Show
Three findings stand out. First, in 2025 psychedelics were the most commonly used illegal drugs in Canada, and psilocybin was the most commonly used psychedelic: 43 percent of people who used any illegal or other substance of concern in the past year reported that psilocybin was the only one they used (Health Canada, 2026a). By comparison, past-year use of MDMA or similar drugs was about 2 percent, and use of ketamine or other dissociatives about 1 percent.
Second, the apparent rise from 6 percent in 2023 to 7 percent in 2025 must be read with care. Health Canada (2026a) notes that the increase may reflect the shift from a grouped question in 2023 to more specific questions in 2025. The lifetime estimates show why the caution is needed. Lifetime use rose from 16.4 percent in 2023 to 26.9 percent in 2025 in the Health Infobase data (Health Canada, 2026b). For that to reflect behaviour, about one in ten people aged 15 or older would have had to try a psychedelic for the first time within two years, which seems unlikely when 7.4 percent reported any use in the past year. A change in how the question was asked is the more plausible explanation. For the same reason, Health Canada advises against comparing CSUS results directly with the 2019 CADS, whose 2 percent estimate came from a different method and a category that included PCP.
Third, use is concentrated in some groups. Figure 1.4 shows past-year use by age in the two CSUS cycles.
In 2025, use was highest at ages 18 to 34, at about 13 percent, and lowest at age 65 or older, at about 1 percent. Between the two cycles the estimates rose most at ages 35 to 64, while the estimate for ages 15 to 17 fell from 9.8 to 8.1 percent, a change within the overlapping confidence intervals for that small group. Interactive 1.2 lets you explore the 2023 and 2025 estimates by other characteristics, with their confidence intervals.
Explore past-year psychedelic use in the Canadian Substance Use Survey
In the 2025 data, past-year use was 8.6 percent among males and 6.2 percent among females, and about 17 percent among gender-diverse respondents and among people who identify as LGBTQ2+, estimates from smaller groups with wide intervals. Use was more than twice as common among people who rated their mental health as fair or poor (13.1 percent) as among those who rated it good, very good or excellent (6.0 percent). A cross-sectional survey cannot show which way this association runs. Some people may use psychedelics to manage distress, use may affect mental health, or shared conditions such as stress, trauma or discrimination may raise both; HSCI 214 examines those conditions. Use also occurs with other drugs: in 2025, 3 percent of the population reported using alcohol and psychedelics on the same occasion (Health Canada, 2026a).
Use Interactive 1.2 to compare the 2023 and 2025 estimates for ages 15 to 17 and for ages 35 to 44. For each age group, note whether the two confidence intervals overlap, and decide how confidently you could tell a news reporter that use changed in that group. Then name one feature of the 2025 questionnaire that would make you cautious even where the intervals do not overlap.
The Canadian survey describes how many people use psychedelics in a given year. Part 7.2 sets these estimates beside data from the United States, where a longer series is available for adults.
7.2 Psychedelic Use Among Adults in the United States
The Monitoring the Future panel study, funded by the National Institute on Drug Abuse and conducted at the University of Michigan, follows a subset of people first surveyed in secondary school into adulthood and collects data each year by online and paper surveys (National Institute on Drug Abuse, 2023). The types of hallucinogen that participants reported included LSD, mescaline, peyote, psilocybin and PCP (University of Michigan, 2024), and the release on the 2022 data also listed MDMA (National Institute on Drug Abuse, 2023).
Among adults aged 19 to 30, past-year hallucinogen use rose from 3 percent in 2012 to 5 percent in 2017 and 8 percent in 2022; among adults aged 35 to 50, it rose from 1 percent or less in 2012 and 2017 to 4 percent in 2022 (National Institute on Drug Abuse, 2023). The 2023 estimates were 9 percent and 4 percent (University of Michigan, 2024), and the study reported that use reached the highest levels recorded in both age groups in 2024 (University of Michigan Institute for Social Research, 2025).
The two series cannot be compared number for number, because they cover different ages and years, use different categories (the American one includes PCP) and recruit respondents differently. Both nevertheless show use concentrated among young adults and becoming more common in mid-life. Part 7.3 turns to one particular way of using psychedelics.
7.3 Microdosing
Microdosing is the practice of regularly taking low doses of a psychedelic (Szigeti et al., 2021), at doses intended to be below the level that produces marked perceptual effects (Rootman et al., 2021). It differs from psychedelic-assisted therapy in nearly every respect described in Section 1: it is usually self-directed, repeated over weeks, and done without screening, supervision or integration.
7.3.1 How Common Is It?
Keyes, Terry-McElrath and Patrick (2026) analyzed 3,094 young adults aged 19 to 30 in the Monitoring the Future panel in 2022 and 2023. Past-year hallucinogen use was reported by 9.5 percent, and at least one occasion of microdosing in the past year by 6.8 percent, and the authors report that 73.1 percent of those who used hallucinogens microdosed at least once. People who microdosed reported much more use of alcohol, cannabis and other drugs than those who did not, which led the authors to raise concerns about the context in which microdosing occurs.
7.3.2 Why Do People Microdose, and Does It Work?
Rootman and colleagues (2021), a team based at the University of British Columbia, recruited 4,050 people who microdosed and 4,653 who did not through a mobile application, using psychedelic podcasts and online conference presentations to reach them. Psilocybin was the substance used by 85 percent of the microdosers, some of whom combined it with other products such as lion’s mane mushrooms, chocolate or niacin, a practice the authors call stacking. Health and wellness motives were the most common. Among participants who reported mental health concerns, those who microdosed reported lower levels of depression, anxiety and stress than those who did not. The design was cross-sectional and the sample self-selected, so the study cannot show that microdosing caused these differences; people who had a good experience may simply have been more likely to keep microdosing and to take part.
A placebo-controlled test of the same question used a different design. Szigeti and colleagues (2021) gave people who already microdosed online instructions for hiding their own doses in opaque capsules mixed with empty placebo capsules, so that they did not know which they were taking on any day. Of 1,630 people who signed up, 191 completed the study, which included a four-week dosing period. Psychological outcomes improved in the microdose group, but they improved in the placebo group as well, with no significant difference between the groups on the main outcomes, and the small differences found on some measures could be explained by participants correctly guessing which capsule they had taken. Lesson 5 examines this self-blinding design and the problem of guessing in detail. Section 4 uses both studies to show how design changes the strength of a claim.
A 2026 systematic review and meta-analysis by Meshkat and colleagues (2026) brought together 24 studies of microdosing in healthy adults. Observational studies reported improvements in mood that the authors judged likely to reflect expectancy or lifestyle, while randomized trials showed no clear benefit over placebo for depressive, anxiety or stress symptoms, and the authors judged the trial evidence inconclusive. The pooled analysis of randomized trials rested on two trials with 117 participants, and research on microdosing is still evolving.
7.4 Retreats and Ceremonies
A second setting is the retreat: an organized program, lasting from one day to more than a week, in which participants take a psychedelic in group sessions led by facilitators (Kettner et al., 2021). Retreats are distinct from Indigenous traditions such as the use of ayahuasca in Amazonian traditional medicine (Bouso et al., 2022), which have their own lineages and meanings; Lesson 2 describes those traditions and the harms that followed outside attention. An Indigenous-led global consensus process has raised concerns about cultural appropriation, the patenting of traditional medicines and the absence of Indigenous leadership in Western psychedelic research and practice, and it identified eight interconnected ethical principles: reverence, respect, responsibility, relevance, regulation, reparation, restoration and reconciliation (Celidwen et al., 2023). Lesson 12 returns to these principles.
Two large observational studies describe retreat and ceremony participants. Kettner and colleagues (2021) surveyed 886 people before and after a psychedelic retreat or ceremony. Psilocybin mushrooms or truffles accounted for 80 percent of the planned substances and ayahuasca for 16 percent, 40 percent of participants had never used a psychedelic before, and a sense of shared humanity during the ceremony correlated modestly with later gains in wellbeing (r = 0.22) and social connectedness (r = 0.25). Bouso and colleagues (2022) analyzed the Global Ayahuasca Survey of 10,836 people from more than 50 countries. Acute physical adverse effects, mainly vomiting, were reported by 69.9 percent, and 2.3 percent needed medical attention afterwards. Adverse mental health effects in the following weeks or months were reported by 55.9 percent, although about 88 percent of those respondents considered them part of a positive process of growth, and about 12 percent sought professional support. Physical adverse effects were more likely when ayahuasca was taken in an unsupervised context, and mental health adverse effects were less likely in religious settings.
Both studies relied on self-selected participants who answered online surveys, so they describe people who chose to take part and cannot estimate how common any outcome is among everyone who attends a retreat. Lesson 11 examines retreats operating in Canada. Part 7.5 turns to the setting that has grown most visibly in Canadian cities.
7.5 Unlicensed Psilocybin Storefronts
Between 2024 and 2025, shops selling psilocybin products to the public without any licence operated in several Canadian cities. Two studies by Matsukubo and colleagues provide systematic counts, and Health Canada has stated its position in writing.
7.5.1 Number, Location and Products
Matsukubo and colleagues (2025) used systematic web searches and media reports to identify 57 psilocybin dispensaries operating in Canada in May 2024, or 0.18 stores per 100,000 people aged 15 or older, in 15 of Canada’s 42 major urban centres; most were in Ontario and British Columbia. Of the 57, 61.4 percent belonged to chains. All of the stores examined sold dried mushrooms, 97.8 percent sold microdosing capsules, and most sold psilocybin chocolate and gummies, with 65.2 percent selling products that mimicked popular food brands. A repeat assessment found 75 stores by July 2025, or 0.24 per 100,000 (Matsukubo et al., 2026). Figure 1.5 shows that the growth came with rapid turnover.
Matsukubo and colleagues (2026) also found that 29.0 percent of residents of Vancouver lived within a ten-minute walk of a store, compared with 9.5 percent in Toronto, and that 49 percent of stores with online listings advertised other psychoactive substances, most often DMT.
7.5.2 Health Claims and Warnings
The 2024 study examined the stores’ websites. Of the 22 websites analyzed, 86.4 percent made at least one mental health claim, most often about anxiety (81.8 percent), depression (77.3 percent) and post-traumatic stress disorder (72.7 percent), and only two referred to a published study (Matsukubo et al., 2025). Warnings were rare where they would matter most: 9.1 percent warned against use while driving, 13.6 percent mentioned pregnancy, and 31.8 percent mentioned a history of psychosis, schizophrenia or bipolar disorder. The authors also noted that the websites very rarely mentioned that the benefits reported in trials came from psychedelic-assisted therapy. Section 4 examines two of these claims with the lesson’s checklist.
7.5.3 Health Canada’s Position
Case 1.2 describes a written statement of the federal position from March 2024.
In March 2024, after a panel of Vancouver city councillors voted to reissue a business licence to a psilocybin dispensary on West Broadway, Health Canada’s Controlled Substances and Opioid Response Directorate wrote to the city manager. The letter, dated 15 March 2024, stated that psilocybin mushrooms are controlled under the CDSA, that storefronts selling psilocybin to the general public are not authorized to do so and may be subject to law enforcement action, and that Health Canada considers that illegally operating storefronts pose a risk to the health and safety of Canadians (Health Canada, 2024b). Health Canada’s public page on psilocybin, modified in October 2025, adds that drugs produced illegally are not tested and may contain other dangerous substances (Health Canada, 2025).
Consider what the letter can and cannot do. It states the law and Health Canada’s view of the risk, but it does not itself close a store or revoke a municipal licence.
Public opinion is one input to the policy debate. In a web panel survey of 3,674 Canadian adults in March 2025, 79.1 percent were unfamiliar with psychedelic stores, respondents were evenly divided between closing the stores and keeping the unregulated status quo, and 66.6 percent supported authorizing sales under a regulatory framework (Gagnon et al., 2026). This course’s practice standard favours a regulated public health model with licensed providers and training standards; Lessons 11 and 12 present that position with the evidence and the counter-arguments, so that students can weigh the policy questions themselves.
Summary
This section showed that in 2025 psychedelics, mainly psilocybin, were the most commonly used illegal drugs in Canada, used in the past year by about 7 percent of people aged 15 or older, and that use was highest among young adults and among people who reported fair or poor mental health. It explained why questionnaire changes make the rise between 2023 and 2025 hard to interpret, and why Canadian and United States estimates cannot be compared directly. It described microdosing, retreats and ceremonies, and unlicensed storefronts as settings of use outside clinics. The evidence on microdosing comes from a national panel survey, a self-selected app-based survey and a placebo-controlled self-blinding study, and a 2026 review found the trial evidence inconclusive; the evidence on retreats comes from self-selected online surveys; and the storefront counts come from systematic web searches and media reports. The section also set out Health Canada’s written position on storefronts as of 2024 and 2025.
Section 4 asks how to judge the claims that circulate about these drugs, from storefront websites to company press releases, and offers a practical checklist for doing so.
Key Takeaways
- 7.1 In the Canadian Substance Use Survey of 2025, 7.4 percent of people aged 15 or older (95 percent CI 7.1 to 7.8) reported past-year psychedelic use, mostly psilocybin, with use highest at ages 18 to 34 and among people who rated their mental health as fair or poor. The 2025 questionnaire asked about specific psychedelics where the 2023 one used a grouped question, so the apparent rise since 2023, and the jump in lifetime use from 16.4 to 26.9 percent, are hard to interpret. Health Canada also advises against direct comparison with the 2019 CADS.
- 7.2 Monitoring the Future found past-year hallucinogen use of 8 percent at ages 19 to 30 and 4 percent at ages 35 to 50 in 2022, rising to record levels by 2024. The American and Canadian series cover different ages and years, use different categories (the American one includes PCP) and recruit differently, so they cannot be compared number for number, although both show use concentrated among young adults and becoming more common in mid-life.
- 7.3 Microdosing is common among young adults who use hallucinogens and is usually self-directed, repeated and unsupervised. A large self-selected app study found lower depression, anxiety and stress among people who microdosed, but its cross-sectional design cannot show cause. In a placebo-controlled self-blinding study, microdose and placebo groups improved to a similar extent.
- 7.4 Surveys of retreat and ceremony participants found that psilocybin and ayahuasca were the main substances, that many participants had never used a psychedelic before, and that acute physical adverse effects were common in the Global Ayahuasca Survey and more likely without supervision. These self-selected online samples cannot estimate how common any outcome is among everyone who attends a retreat, and Indigenous traditions have their own lineages and ethical principles distinct from commercial retreats.
- 7.5 Unlicensed psilocybin storefronts in Canada grew from 57 in May 2024 to 75 by July 2025, with rapid turnover and most stores in Ontario and British Columbia. In 2024, 86.4 percent of store websites examined made mental health claims while warnings were rare. Health Canada wrote on 15 March 2024 that such storefronts are not authorized and pose a risk to health and safety.
Reflection
A hypothetical city councillor in British Columbia cites these figures. In the Canadian Substance Use Survey, past-year use of any psychedelic was 6.0 percent in 2023 and 7.4 percent in 2025 (95 percent confidence interval 7.1 to 7.8); Health Canada notes that the 2025 questionnaire asked about specific psychedelics where the 2023 questionnaire used one grouped question. Lifetime use was 16.4 percent in 2023 and 26.9 percent in 2025. In 2025, past-year use was 13.1 percent (95 percent confidence interval 12.0 to 14.4) among people who rated their mental health as fair or poor and 6.0 percent (5.8 to 6.3) among others. Unlicensed psilocybin stores in Canada rose from 57 in May 2024 to 75 in July 2025, and in 2024, 86.4 percent of 22 store websites claimed mental health benefits. The councillor says the numbers prove that storefronts caused a surge in psychedelic use and that people with poor mental health are being harmed by it. In 150 to 250 words, explain what these data can and cannot show, and name one additional source of evidence that would help answer the councillor’s question.
The data show that psychedelic use, mostly of psilocybin, was common in Canada in 2025 and that unlicensed stores multiplied between 2024 and 2025. They do not show that stores caused an increase in use. The rise from 6.0 to 7.4 percent coincides with a change from a grouped question to specific questions, and Health Canada itself cautions that the change may explain part of the difference. The lifetime figure makes the point clearly: a jump from 16.4 to 26.9 percent in two years would require about one person in ten to try a psychedelic for the first time, which is implausible when 7.4 percent reported any past-year use. The survey also cannot link any individual’s use to a store.
The association with mental health is clear in these data, since the intervals do not overlap. Its direction is unknown. People in distress may seek out psychedelics, use may affect mental health, or stress, trauma or discrimination may raise both. The claims on store websites, which rarely cite evidence, are a separate concern.
Useful additional evidence would include future survey cycles that keep the 2025 wording, so that change can be measured on the same questions, combined with data linking store openings by area to local survey estimates or to emergency department visits over time.
Minimum 20 characters required.
Question 1: Why does Health Canada advise caution in interpreting the rise in past-year psychedelic use from 6 percent in 2023 to 7 percent in 2025?
Question 2: In the 2025 survey, past-year psychedelic use was 13.1 percent among people with fair or poor self-rated mental health and 6.0 percent among others. Which interpretation is best supported?
Question 3: What did Szigeti and colleagues (2021) find in their self-blinding study of microdosing?
Question 4: What did Matsukubo and colleagues (2025) find about the websites of Canadian psilocybin dispensaries in 2024?
Weighing Claims: The Renewed Research Era, the Hype Cycle and a Practical Checklist
Introduction
Claims about psychedelics reach students, clients and policymakers from many directions: university press releases, company announcements to investors, news headlines, storefront websites and the accounts of friends. Some claims rest on randomized trials, some on surveys, and some on nothing that can be checked. This section gives a practical way to tell them apart.
Part 8.1 describes the growth of research and investment since 2000. Part 8.2 explains the hype cycle and why researchers in the field have warned about it. Part 8.3 sets out a six-item checklist, illustrated with studies from earlier sections, and Part 8.4 adds supporting questions and explains how to treat company-reported results and press releases. Part 8.5 asks you to apply the checklist to six real claims and to summarize one accurately, and the section closes with a task that draws on the whole lesson. Lessons 5 and 8 develop blinding and the interpretation of trial results in more depth.
Learning Objectives
- 8.1 Describe the growth of psychedelic research since 2000 using publication counts, and identify the commercial interests that have accompanied it.
- 8.2 Explain the hype cycle and the argument of Yaden, Potash and Griffiths (2022) that psychedelic research is caught in a hype bubble.
- 8.3 Apply a six-item checklist (design, comparator, blinding, sample, follow-up and funding) to a claim about psychedelics or psychedelic-assisted therapy.
- 8.4 Distinguish peer-reviewed trial reports from company-reported results, institutional press releases and marketing statements.
- 8.5 Write a summary of a claim that states accurately how strong its evidence is.
8.1 The Renewed Research Era
After a long pause that Lesson 2 describes, research on psychedelics resumed in the 2000s and accelerated in the 2010s. Publication counts give one simple measure of that change.
Figure 1.6 shows the number of records in PubMed, the United States National Library of Medicine’s database of biomedical literature, with the word psilocybin in the title or abstract, for each year from 2000 to 2025. The search was run for this lesson on 17 October 2026.
The count stayed between 7 and 19 records a year until 2012, then rose to 31 in 2015, 125 in 2020 and 601 in 2025. Part of this growth reflects the growth of publishing in general: PubMed holds about 3.5 times as many records for 2025 as for 2000 (1,881,957 against 532,636). Even so, psilocybin records rose from about 1.7 per 100,000 PubMed records in 2000 to about 31.9 per 100,000 in 2025, so the topic’s share of the literature grew roughly nineteen-fold. A publication count measures attention, however, and attention is not evidence. In a search run on 18 October 2026, 212 of the 601 records for 2025 were indexed in PubMed as reviews, and 34 as clinical trials or randomized controlled trials.
Commercial interest grew alongside the research. A phase 2 trial of single-dose psilocybin for treatment-resistant depression, reported by Goodwin and colleagues (2022), was funded by the drug’s developer, COMPASS Pathfinder, and the developer, Compass Pathways, reported the result of a phase 3 trial (COMP005) to investors in a filing with the United States Securities and Exchange Commission in June 2025 (Compass Pathways, 2025). As of July 2026, the company was reported to have begun a rolling new drug application to the FDA, with completion expected in the fourth quarter of 2026 (PharmaTimes, 2026). In Canada, the retail market described in Section 3 is also commercial, with two chains running 44 percent of unlicensed psilocybin stores in 2025 (Matsukubo et al., 2026). Yaden, Potash and Griffiths (2022) note that news articles have mentioned the investment potential of psychedelics reaching billions of dollars. Funding from an interested party does not make a finding false. It does give some people a stake in how a finding is presented, which is why funding is one item in the checklist in Part 8.3.
8.2 The Hype Cycle
Rapid growth in attention and investment tends to produce a recognizable pattern. The technology research firm Gartner describes this pattern as a hype cycle with five phases, and researchers in the psychedelic field have used the idea to describe their own situation.
Figure 1.7 draws the cycle schematically. In Gartner’s description, an innovation trigger sparks early stories and media attention before usable products exist; a peak of inflated expectations brings success stories alongside many failures; a trough of disillusionment follows as trials and implementations underdeliver; a slope of enlightenment brings clearer understanding of where the technology helps; and a plateau of productivity arrives with mainstream adoption and clearer criteria for judging the technology (Gartner, n.d.).
Yaden, Potash and Griffiths (2022), writing in JAMA Psychiatry, argued that psychedelic research “currently appears to be trapped in a hype bubble driven largely by media and industry interests.” They observed that media coverage had swung from alarm to excessive optimism, with articles describing psychedelics as a cure or a miracle drug, and that such extreme shifts in perception can obstruct rigorous science and reasonable clinical use. They asked researchers and clinicians to counter claims that the evidence does not support and to practise careful science communication. The hype cycle also predicts a trough, in which genuine but modest benefits may be dismissed along with exaggerated ones.
Case 1.3 describes one moment at which high expectations met a regulator’s review.
On 4 June 2024, the FDA’s Psychopharmacologic Drugs Advisory Committee reviewed the application for MDMA-assisted therapy for post-traumatic stress disorder. It voted 2 to 9 that the evidence showed the treatment was effective and 1 to 10 that its benefits outweighed its risks. Members cited functional unblinding (many participants could tell whether they had received MDMA), possible bias, unanswered questions about abuse potential (the regulatory term for a drug’s likelihood of non-medical use), and little evidence about the contribution of the psychological component, and some researchers also criticized the sponsor for adverse events that had not been reported (Pharmaceutical Executive, 2024). In August 2024 the FDA declined to approve the application and asked for another phase 3 trial (Fierce Biotech, 2024).
A phase 3 trial reported by Mitchell and colleagues (2021) had found a large difference from placebo. The committee’s concerns were about whether the design could show that the difference was caused by the drug. Lesson 9 examines the evidence, the decision and what followed.
Case 1.3 shows that a strong-looking result can still leave reviewers uncertain when blinding, adverse event recording and the role of each treatment component are in doubt. Part 8.3 turns those concerns into questions that anyone can ask of a claim.
8.3 A Checklist for Weighing Claims
The checklist in Table 1.5 asks six questions. None requires statistical training, and each can usually be answered from the abstract of a study or the text of a press release. The examples in the last column come from studies already discussed in this lesson.
Table 1.5. A six-item checklist for weighing a claim about psychedelics or psychedelic-assisted therapy, with an example of each item from this lesson.
| Item | Question to ask | Stronger evidence | Weaker evidence | Example from this lesson |
|---|---|---|---|---|
| Design | How was the evidence produced? | Randomized controlled trial, ideally replicated | Open-label study, survey, case report or testimonial | An open-label pilot found 12 of 15 smokers (80 percent) abstinent at six months, measured as seven-day point prevalence abstinence, and its authors noted that the design does not allow definitive conclusions about efficacy (Johnson et al., 2014). |
| Comparator | Compared with what? | Placebo, an active placebo, a low dose or an established treatment | No comparison group, or a group chosen differently | Against daily escitalopram, psilocybin did not differ significantly on the primary outcome (mean changes of −8.0 and −6.0 points, a difference of −2.0 points; 95 percent CI −5.0 to 0.9), although secondary outcomes favoured psilocybin without correction for multiple comparisons (Carhart-Harris et al., 2021). |
| Blinding | Did participants and raters know who received what? | Blinding maintained and checked | Open-label, or blinding likely broken | In the self-blinding study, participants guessed their capsule correctly 72 percent of the time, above the 62 to 63 percent expected from random guessing (Szigeti et al., 2021). |
| Sample | How many people, and who? | Large enough for precise estimates; similar to the people the claim is about | Small or highly selected samples | The brain-imaging study behind the “reset” claim had usable data from 16 of 19 patients and no control condition (Carhart-Harris et al., 2017). |
| Follow-up | How long were people followed? | Long enough to show whether benefits last | Days or a few weeks | A single 25 mg dose reduced depression scores at week 3, but sustained response at 12 weeks did not clearly support the primary result (Goodwin et al., 2022). |
| Funding | Who paid, who reported, and are conflicts disclosed? | Independent or disclosed funding; peer-reviewed report | Sponsor’s own announcement; undisclosed interests; a seller’s claim | The microdosing app study disclosed that a co-author was an applicant on pending patents combining psilocybin, lion’s mane and niacin, one of the stacking practices it described (Rootman et al., 2021). |
Each item has a reason behind it. Design matters because only randomization balances the known and unknown differences between groups. Comparators matter because people in comparison groups also improve, as both groups did in the escitalopram trial and in the self-blinding study, so a claim that a treatment helped needs a group that received something else. Blinding matters because expectations shape outcomes, especially self-rated ones, and Lesson 5 shows why blinding is hard when a drug’s effects are unmistakable. Sample size matters because studies with low statistical power tend to overestimate effects and are less likely to be reproduced (Button et al., 2013). Follow-up matters because a treatment given once must show that its benefit lasts. Funding matters because a Cochrane review found that industry-sponsored drug and device studies more often reported favourable efficacy results (risk ratio 1.27) and favourable conclusions (risk ratio 1.34) than studies with other sponsors (Lundh et al., 2017).
8.4 Supporting Questions and Company-Reported Results
The six items are not the only questions worth asking. The accordion below adds three more that often decide whether a sound study supports a particular claim.
Trial participants are screened, often have no psychotic disorder or serious heart disease, and receive psychological support. A result from such a trial says little about a person buying capsules in a storefront. Lesson 6 explains screening, and Lesson 8 examines the gap between trial and clinic populations.
A claim about depression may rest on a self-rated questionnaire or on a clinician’s interview, and a difference of a few points on a 60-point scale may or may not matter to patients. Lesson 8 explains response, remission and the number needed to treat.
A peer-reviewed trial report has been checked by independent reviewers and includes methods and limitations. A press release summarizes selected results, and a storefront website is advertising. The box after these questions explains how this course treats company-reported results.
Company-reported results and press releases
Companies often announce trial results before the full report is peer-reviewed, because they must inform investors. This course uses such announcements only for a company’s own unpublished trial results, and labels them as company-reported. Compass Pathways’ filing of June 2025, for example, reported that in its COMP005 trial, 258 participants with treatment-resistant depression received a single 25 mg dose of COMP360 or placebo, and that the mean difference in change on the Montgomery-Åsberg Depression Rating Scale (MADRS, scored from 0 to 60) at week 6 was −3.6 points (95 percent CI −5.7 to −1.5). The same filing stated that the FDA had not yet reviewed the data and that 26-week results were still to come (Compass Pathways, 2025). The company reported 26-week results for COMP005 in February 2026 (Compass Pathways, 2026) and six-month results from a second phase 3 trial, COMP006, in July 2026 (PharmaTimes, 2026), and both were again company-reported, so the evidence for this product was still evolving in October 2026. A reader should treat such numbers as the sponsor’s preliminary summary until the full report appears, and should check the date of every claim, because results in this field appear quickly.
University press releases are a different case. They describe peer-reviewed work, but they choose the framing, and a short headline can drop the caveats that the paper itself states.
With the checklist and its supporting questions in hand, Part 8.5 asks you to apply them to six real claims.
8.5 Applying the Checklist
Interactive 1.3 presents six claims that circulated between 2017 and 2025: two university press releases, one company announcement, one study title and two statements from Canadian psilocybin dispensary websites reproduced by Matsukubo and colleagues (2025). Each card summarizes the evidence behind the claim. Rate each checklist item, then compare your ratings with the analysis.
Claim evaluator: six real claims against the checklist
Most claims fall short on several items, and the ones that fall short on most items are the least specific about their evidence. The two university press releases were hedged (“may”, “suggests”) and pointed to published studies whose authors listed their limitations; the storefront statements cited nothing. A careful summary carries the hedges forward and names the design.
Rewrite the 2017 press-release headline, “‘Magic mushrooms’ may ‘reset’ the brains of depressed patients, study suggests,” as one accurate sentence of no more than 30 words. Your sentence should name the design, the number of patients and what was measured, using the evidence summarized on its card in Interactive 1.3.
“In a small open-label study without a control group, brain scans of 16 patients with treatment-resistant depression changed after two psilocybin doses given with psychological support.” The sentence keeps the finding and states the three features that limit it: no comparison group, open-label dosing and a small sample.
Summary
This section showed that research on psilocybin has grown far faster than the biomedical literature as a whole since 2015, alongside substantial commercial interest, and explained the hype cycle that Yaden, Potash and Griffiths (2022) used to describe the field. It set out a six-item checklist (design, comparator, blinding, sample, follow-up and funding), with three supporting questions about population, outcome and venue, and applied it to six real claims, from storefront statements to a phase 3 announcement.
A Canadian psilocybin dispensary website, reproduced by Matsukubo and colleagues (2025), states: “Psilocybin is a potent tool to cure severe cases of depression and PTSD.” Draw on all four sections to prepare a short evidence note for a hypothetical community health centre in British Columbia. Classify psilocybin and state how it acts (Section 1); explain how the trial use of psilocybin differed from buying it in a store, including the single supervised dose with psychological support in the trial of Goodwin and colleagues (2022) (Sections 1 and 3); say what the Canadian Substance Use Survey shows about who uses psilocybin and what Health Canada says about storefronts (Section 3); rate the claim on the six checklist items (Section 4); and name the lawful routes to psychedelic-assisted therapy in Canada (Section 1, 4.1 Where Psychedelic-Assisted Therapy Is Lawful in Canada). Avoid giving any advice about use.
The section reflection and knowledge check follow. The final assessment then asks you to bring together definitions, measures of experience, patterns of use and the checklist, and Lesson 2 traces the histories from which the current research era emerged.
Key Takeaways
- 8.1 PubMed records with psilocybin in the title or abstract rose from between 7 and 19 a year until 2012 to 601 in 2025, a roughly nineteen-fold growth in the topic’s share of the literature. Commercial interest grew alongside, from developer-funded trials and filings to investors to retail chains running storefronts. A publication count measures attention, not evidence, and funding from an interested party gives some people a stake in how a finding is presented.
- 8.2 Gartner’s hype cycle runs from an innovation trigger through a peak of inflated expectations and a trough of disillusionment to a slope of enlightenment and a plateau of productivity. Yaden, Potash and Griffiths (2022) argued that psychedelic research appears trapped in a hype bubble driven largely by media and industry interests, and the 2024 FDA advisory committee review of MDMA-assisted therapy shows high expectations meeting a regulator’s doubts about blinding, adverse events and the role of therapy.
- 8.3 A claim can be weighed by asking six questions: how the evidence was produced (design), compared with what (comparator), whether people knew what they received (blinding), how many and who (sample), for how long (follow-up), and who paid and reported (funding). None requires statistical training, and each can usually be answered from an abstract or a press release.
- 8.4 Who was studied, what outcome was measured and where the claim was reported often decide whether a sound study supports a particular claim. A peer-reviewed trial report includes methods and limitations; a company announcement is the sponsor’s preliminary summary and is labelled as company-reported; a press release chooses its framing; and a storefront website is advertising.
- 8.5 Applied to six real claims, the checklist shows that most fall short on several items, and the claims that cite nothing fall short most often. An accurate summary carries the original hedges forward and names the design, the sample and what was measured, as in a rewrite of the 2017 “reset” headline that states it came from a small open-label study without a control group.
Reflection
A company press release from June 2025 is headlined “Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression.” The underlying facts are these: 258 participants at 32 sites were dosed, 171 with a single 25 mg dose of COMP360 and 87 with placebo, under double-blind conditions; the mean difference in change on the Montgomery-Åsberg Depression Rating Scale (scored 0 to 60) at week 6 was −3.6 points (95 percent confidence interval −5.7 to −1.5); 26-week results were not yet available at the time (the company reported them in February 2026, again before peer review); the results were reported by the company before peer review, and the FDA had not yet reviewed them. In an earlier phase 2 trial, a single 25 mg dose reduced scores by 6.6 points more than a 1 mg dose at week 3, but sustained response at 12 weeks did not clearly support that result (Goodwin et al., 2022). Rate each of the six checklist items (design, comparator, blinding, sample, follow-up and funding) as meeting the standard, falling short or impossible to judge from this information, giving one sentence of reasons for each, and then write a one-sentence headline that states the strength of the evidence accurately.
Design meets the standard: a randomized, double-blind phase 3 trial is the strongest design available for this question. Comparator meets the standard, because placebo allows the drug’s effect to be separated from improvement over time and from attention. Blinding cannot be judged from the release: the design was double-blind, but a single strong psilocybin experience is easy to recognize, and the release does not report whether participants guessed their allocation. Sample meets the standard; 258 participants is large for this field, although they were screened adults with treatment-resistant depression. Follow-up falls short for this release, because the result rests on six weeks after one dose, and the phase 2 trial showed that early differences may not be sustained; the 26-week results that followed in February 2026 were also the company’s own report. Funding falls short as a source, because the sponsor reported its own result before peer review and regulatory review.
A more accurate headline would be: “In a company-reported, placebo-controlled trial of 258 adults with treatment-resistant depression, one dose of psilocybin reduced depression scores by 3.6 points more than placebo at six weeks; longer-term results were still to come.”
Minimum 20 characters required.
Question 1: Johnson and colleagues (2014) reported that 12 of 15 participants were abstinent from smoking at six months (seven-day point prevalence abstinence). Which checklist item most limits this claim?
Question 2: What did Lundh and colleagues (2017) report in their Cochrane review of industry sponsorship?
Question 3: According to Yaden, Potash and Griffiths (2022), what has largely driven the hype bubble around psychedelic research?
Question 4: A press release states that a company’s phase 3 trial met its primary endpoint, with a 3.6-point difference from placebo at week 6. How does this course treat such a result?
Final Assessment
Bringing It All Together
This lesson set out the vocabulary and the habits of evidence that the rest of the course depends on. Section 1 defined the classic psychedelics by their action at the serotonin 2A receptor and separated them from the entactogen MDMA, the dissociative ketamine and the atypical agents ibogaine and salvinorin A, then showed that Canadian law and national surveys sort the same drugs differently. It defined psychedelic-assisted therapy as a phased process in which one or a few supervised doses sit inside screening, preparation and integration, and it named the routes through which that therapy can lawfully take place in Canada.
Section 2 explained how researchers measure the experience with the 5D-ASC, the MEQ30, the Ego Dissolution Inventory and the Challenging Experience Questionnaire, and how user-reported sources such as PsychonautWiki describe it. Section 3 turned to the people who use psychedelics, from the 2.6 million Canadians reporting past-year use in 2025 to microdosing, retreats and the unlicensed storefronts documented in 2024 and 2025. Section 4 placed these findings in the context of a fast-growing and commercially interested field and gave a six-item checklist for weighing any claim.
The final reflection and knowledge assessment below ask you to combine these parts: to classify a drug, describe what its effects are and how they are measured, place a claim in the context of real patterns of use, and judge the evidence behind it.
Key Takeaways from this lesson
- Classic psychedelics, including psilocybin, LSD, DMT and mescaline, form a pharmacological class because they act as agonists or partial agonists at serotonin 2A receptors, even though they come from three chemical families. MDMA, ketamine, ibogaine and salvinorin A produce related experiences through different primary mechanisms, so findings about one drug cannot be transferred to the others.
- The Controlled Drugs and Substances Act and national surveys sort these drugs into categories that do not follow pharmacology, and readers need to know which system a source uses.
- Psychedelic-assisted therapy places one or a few supervised dosing sessions inside a course of screening, preparation and integration, which makes it a different model of treatment from a daily medication and from supervised esketamine.
- As of October 2026, psychedelic-assisted therapy with psilocybin or MDMA can lawfully take place in Canada only through clinical trials, the Special Access Program or subsection 56(1) exemptions.
- Psychedelics change perception, emotion, cognition and the sense of self, and research scales such as the 5D-ASC, MEQ30, Ego Dissolution Inventory and Challenging Experience Questionnaire make these experiences comparable across doses, drugs and people; the MEQ30 criterion for a complete mystical experience requires at least 60 percent of the maximum on every factor.
- The items of research scales reflect researchers’ choices and their ratings are retrospective, while user-reported sources such as PsychonautWiki, Erowid and TripSit document vocabulary, experiences and harm reduction information and are never evidence of how often an effect occurs or that a drug is effective or safe.
- About 7 percent of people in Canada aged 15 or older reported past-year psychedelic use in 2025, mostly psilocybin, and changes in the questionnaire make the apparent rise since 2023 difficult to interpret. Evidence on microdosing and retreats comes mainly from surveys and one placebo-controlled self-blinding study, in which microdose and placebo groups improved to a similar extent, and a 2026 review found the trial evidence on microdosing inconclusive; the storefront counts come from systematic web searches.
- Attention to psychedelic research has grown fast enough to fit the hype cycle, and a claim about psychedelics can be weighed by asking about its design, comparator, blinding, sample, follow-up and funding, and by checking whether it is peer-reviewed, company-reported or a seller’s statement.
Core Concepts Reviewed
Section 1: classic serotonergic psychedelics, the 5-HT2A receptor, entactogens, dissociatives, atypical agents, prodrugs, Canadian drug schedules and survey categories, psychedelic-assisted therapy and its phases, and the authorized routes of access in Canada.
Section 2: perceptual, emotional, cognitive and self-related effects, the 5D-ASC and its lower-order scales, the MEQ30 and the complete mystical experience criterion, the Ego Dissolution Inventory, the Challenging Experience Questionnaire, and user-reported sources and their limits.
Section 3: past-year and lifetime prevalence, confidence intervals, weighting and non-response, the Canadian Substance Use Survey and Monitoring the Future, microdosing and self-blinding, retreats and the Global Ayahuasca Survey, and unlicensed psilocybin storefronts.
Section 4: the growth of psychedelic research, commercial interests, the hype cycle, the six-item checklist of design, comparator, blinding, sample, follow-up and funding, functional unblinding, and company-reported results.
The final reflection asks you to respond to a set of everyday claims using evidence from all four sections.
Reflection
A hypothetical friend in Vancouver tells you three things: that a store near their home sells psilocybin microdosing capsules “for anxiety”, that “psychedelics are basically antidepressants that work faster”, and that “everyone is doing it now”. Write 200 to 300 words that respond respectfully and accurately, drawing on all four sections. Use these facts: psilocybin is converted to psilocin, which activates serotonin 2A receptors; in trials, psilocybin was given once or twice in a supervised session with psychological support to screened participants (Goodwin et al., 2022; Carhart-Harris et al., 2021); in the Canadian Substance Use Survey of 2025, 7 percent of people aged 15 or older reported past-year psychedelic use, with about 13 percent at ages 18 to 34; Health Canada wrote on 15 March 2024 that storefronts selling psilocybin are not authorized under the Controlled Drugs and Substances Act; in a self-blinding study, microdose and placebo groups improved to a similar extent (Szigeti et al., 2021); a 2026 meta-analysis found no clear benefit of microdosing over placebo in randomized trials with healthy adults (Meshkat et al., 2026); user reports cannot establish how often an effect occurs or that a product is effective or safe; and, as of October 2026, the authorized routes in Canada are clinical trials, the Special Access Program and subsection 56(1) exemptions. Do not give advice about using any drug.
I would start by agreeing that interest in psilocybin is real and that many people are curious about it. Psilocybin is converted in the body to psilocin, which activates serotonin 2A receptors. That is a different mechanism from an antidepressant such as escitalopram, which is taken every day. In the trials that reported benefits, psilocybin was given once or twice to screened participants in a long supervised session, with psychological support before and after. The support, screening and follow-up were part of the treatment, and none of that comes with a capsule bought in a store.
On microdosing for anxiety, one controlled study had people who already microdosed mix their capsules with placebos without knowing which was which. Both groups improved to a similar degree, which suggests that expectations explain much of the reported benefit, and a 2026 review of randomized trials in healthy adults also found no clear benefit over placebo, although research on microdosing is still evolving. Reports from other people who microdose show what people experience, but they cannot show how often a benefit occurs or that a product is safe, and Health Canada notes that illegally produced drugs are not tested.
“Everyone” is also an overstatement. In the 2025 national survey, about 7 percent of people aged 15 or older reported using a psychedelic in the past year, and about 13 percent of people aged 18 to 34. That is a substantial number, but it is a minority.
Finally, the store is not authorized: Health Canada wrote in March 2024 that storefronts selling psilocybin are not permitted under the Controlled Drugs and Substances Act. As of October 2026, psilocybin-assisted therapy can lawfully take place in Canada through clinical trials, the Special Access Program or a section 56 exemption, and anyone concerned about anxiety can start by speaking with their own health care provider about the options available to them.
Minimum 30 characters required.
Final Knowledge Assessment
Question 1: A hypothetical news story says that ketamine, MDMA and psilocybin “all work by flooding the brain with serotonin.” Which correction is accurate?
Question 2: Which pairing of a substance with its status under the Controlled Drugs and Substances Act (consolidated to 30 September 2026) is correct?
Question 3: Beyond any change in behaviour, why does the 2019 Canadian Alcohol and Drugs Survey estimate of hallucinogen use differ in meaning from the 2025 Canadian Substance Use Survey estimate of psychedelic use?
Question 4: Which feature of psychedelic-assisted therapy does the protocol of Mitchell and colleagues (2021) illustrate?
Question 5: In the pooled data of Studerus and colleagues (2010), which lower-order scales correlated most strongly with the dread of ego dissolution dimension?
Question 6: Nour and colleagues (2016) found that Ego Dissolution Inventory scores rose with dose for psychedelics but not for cocaine or alcohol. What does this finding mainly support?
Question 7: A hypothetical client says PsychonautWiki describes an effect called “thought loops” and asks whether it is common. Which reply is most accurate?
Question 8: Which statement about the 2025 cycle of the Canadian Substance Use Survey is correct?
Question 9: What did Keyes, Terry-McElrath and Patrick (2026) report about microdosing among United States adults aged 19 to 30 in 2022 and 2023?
Question 10: Rootman and colleagues (2021) found lower depression and anxiety among microdosers with mental health concerns. Which checklist items most limit a causal reading of this finding?
Question 11: Which finding did Bouso and colleagues (2022) report from the Global Ayahuasca Survey?
Question 12: At the FDA advisory committee meeting of June 2024 (Case 1.3), members were concerned that many participants could tell whether they had received MDMA. Which checklist item does this concern address most directly?
Question 13: What did Health Canada’s letter of 15 March 2024 to the City of Vancouver state?
Question 14: Which change between the 2023 and 2025 survey cycles best shows why an estimate must be read alongside the questionnaire that produced it?
Question 15: Which summary of the June 2025 COMP005 announcement best applies the lesson’s checklist?
Glossary: Key Terms, People & Frameworks
📚 Reference page, available throughout the lesson
Definitions of the terms, measures, people and frameworks introduced in this lesson, in the sense in which this course uses them.